{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-019030","form_type":"8-K","ticker":"FBIO","cik":"0001429260","company_name":"Fortress Biotech, Inc.","filed_at":"2023-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.045462+00:00","generated_at":"2026-06-08T03:21:43.363495+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Fortress Biotech Q3 net revenue $34.8M (up 100% QoQ); net loss narrows to $7.1M","bullets":["Total consolidated net revenue $34.8M, including $19M upfront payment from Journey Medical's Maruho license.","Net loss attributable to common stockholders $7.1M ($0.94/share) vs $24.5M ($4.11) in Q3 2022.","Cash, equivalents and restricted cash $74.7M at Sept 30; subsequent public offering raised $10M in Nov 2023.","NDA for DFD-29 (rosacea) expected around year-end 2023; cosibelimab PDUFA date Jan 3, 2024.","Effected 1-for-15 reverse stock split in Oct 2023 to meet Nasdaq minimum bid price requirement."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-019030","json":"https://secwatch.observer/filing/0001558370-23-019030.json","markdown":"https://secwatch.observer/filing/0001558370-23-019030.md","text":"https://secwatch.observer/filing/0001558370-23-019030.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1429260/000155837023019030/0001558370-23-019030-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1429260/000155837023019030/fbio-20231114x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T03:21:43.363495+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fbb88d95ccc33f14f6776fe917519e439963775c","claim":"Fortress Biotech, Inc. reported third quarter ended September 30, 2023 results: revenue $34.8 million.","evidence_excerpt":"in such filing. ​ --- EX-99.1 (EX-99.1) --- Fortress Biotech Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights ​ Total consolidated net revenue was $34.8 million in the third quarter of 2023, a 100% increase from total consolidated net revenue of $17.4 million in the second quarter of 2023 ​ Fortress is advancing several late-stage","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1429260/000155837023019030/0001558370-23-019030-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Revenue","value":"$34.8 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}